VX-522 was the first program in Moderna’s inhaled pulmonary therapeutics modality, and was never joined by any other candidates. (iStock/Getty Images Plus) After pausing a trial for a ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Maddy Buxton, Culture & Trends manager at YouTube, discusses how creators and digital animation on the platform are global, fan-driven, popular among young adults, and driving innovation and ...

A Vertex Pharmaceuticals immunology drug in clinical testing for a rare kidney disease is catching up to others that work in a similar way, but the company contends its therapy can be best in its ...

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease. Vertex ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Vertex said Monday that a drug it secured ...

March 9 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab said on Monday that its experimental drug sharply reduced a key sign of kidney damage in a late‑stage ‌trial, putting the company on ...

I’ve had my Shark Rocket HV301 for seven years, and it has never let me down on hardwood floors, high-pile area rugs, or tile. Recently, I moved into a larger apartment with more furniture, more ...

Now, here's the reason I would buy and hold Vertex for the long term. It might surprise you when I say it doesn't have to do with the company's work beyond CF. Instead, I would hold onto this company ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Vertex executives warned that Casgevy, its ...